| The First Department Clinical StudyObjective: To study the clinical therapeutic effect of Shuganheweifang on Bile Reflux Gastritis (BRG) of stagnated heat in liver and stomach type.Method: The case-control study was adopted. The selected cases were randomly divided into two groups according to"Randomized Number Scale": 30 patients in treatment group were administered with Shuganheweifang (including chaihu, huangqin,baishao, gualou, banxia, huanglian, yinchen, yujin, lizhihe, suye, zhishi, chenpi, jineijin) and patients in control group were administered with cisapride. All patients were treated for eight weeks. During the therapy, no other pro-motility medicines were taken. Clinical symptoms and gastroscope before and after treatment were detected respectively to evaluate the therapeutic effects. The plasma MTL,CCK level was investigated before and after therapy respectively in the patients. Join 0.3mol/L EDTA 60μL andanti-peptide enzyme 60μL in advance into the test tube to prevent clotting. On the gastric empty examination date, phlebotomized venous blood 4ml in the morning after a night fasting. Set the blood into the preventive clotting tube and set it immediately to the ice and water mixture. Centrifuged at 2500r/minfor 20min under 4℃.Took the blood plasma and preserved it at -20℃for later measurement. The method of radio-immunal test performed according to theoperation explanation. Record the side effects of the medicine during therapy.Result: (1) Clinical symptom therapeutic effect: In treatment group the total efficiency is 93.3%, which is higher than that of control group. In control group the total efficiency is 70.0%. There was a significant difference between two groups (P<0.05). (2) Compared the gastroscopy before and after treatment: There was a significant difference between treatment and control group on the changing of gastroscopy (P<0.05).(3) The change of plasma MTL and plasma CCK level: Both of two groups plasma MTL level significantly increased after therapy(P<0.05).After therapy, plasma MTL level of treatment group was significantly higher than before,(226.37±39.14)pg/ml vs(324.13±15.44)pg/ml (P<0.05), and the change of treatment group was more significant than control group(P<0.05). And both of two groups plasma CCK level significantly decreased after therapy(P<0.05) After therapy, plasma CCK level of treatment group was significantly lower than before ,(5.73±1.66)pmol/L vs(2.66±0.85)pmol/L,(P<0.05)and was significant than control group. (4)Evaluate therapeutic safety in two groups: There were neither obvious changes in blood, urine, stool rules before and after treatment nor in Electrocardiogram and liver-renal function. In the course of the treatment, all patients had no undesirable response, which pointed that both the two groups have no toxic and side effect.Conclusion: This clinical research indicates that Shuganheweifan can improve patient's clinical symptom distinguishly, which has significant difference from cisapride. And it can make the BRG patients'plasma MTL increased and the plasma CCK decreased. This finding authenticated the clinical utility and feasibility of Shuganheweifang and hinted that chinese medicine has conspicuous ascendency on this disease . Then deep study and approach are deserved .The Second Department Experimental StudyObjective: To explore mechanism of Shuganheweifang in curing experimental rat model of Bile Reflux Gastritis (BRG) by constructing animal model and observing gut hormone. The aim is to provide experimental evidence for clinical research.Method: 40 healthy male Wistar rats were randomly divided into four groups which are large dose group, low dose group, model group and normal group, and each group had 10 rats. Animal experiment was adopted Sodium Tauroglycoch-olate, Pancreatin and Lecithin that fills stomach bring out model of BRG. 1 week later when the models were established, the amount of dried medicinal herb given to rats in large dose group and low dose groups were 30g/kg weight and 15g/kg weight respectively. The normal saline was given to normal group and model group respectively. One week later, all rats were killed to observe following index: weight, plasma motilin (MTL) and serum gastrin (GAS)Result:(1) Weight change of rats: After treatment ,compared to the weights before models established, there was no significant difference between model groups and normal group in the weights change of rats(P>0.05), and either between both of two herb groups and normal group(P>0.05).(2) Level of plasma MTL : After treatment, the plasma MTL ([230.6±35.48)pg/ml & ( 228.5±29.98 ) pg/ml vs(180.3±26.96)pg/ml vs(227.6±16.97) pg/ml] of two herb groups was markedly higher than that of model group(P<0.05),while there was no significant difference between two herb groups and normal group(P>0.05). There was no significant difference between large dose herb group and low dose herb group(P>0.05). (3) Level of serum GAS: After treatment, the level of serum GAS [(113.4±10.55)pg/ml&(112.9±11.85)pg/ml vs(81.5±13.88) vs(121.0±10.17) pg/ml] of two herb groups was markedly higher than that of model group(P<0.05),while there was no significant difference between two herb groups and normal group(P>0.05). There was no significant difference between large dose herb group and low dose herb group(P>0.05).Conclusion: This study indicated that Shuganheweifang is able to regulate the level of plasma MTL serum GAS. This kind of gut hormone can strengthen the nutrition and the defence function of gastric mucosa and adjust the movement of bowel and promot the sport of stomach intestines, then can make it empty quickly and alleviate the damage of gastric mucosa.
|
PDF Full Text Request